Charles River joins FDA research effort: November 4 tests Charles River Laboratories stock

Published on 10/25/2026 at 03:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A research agreement with FDA and Labcorp will refine abuse-potential tools. Charles River Laboratories stock faces November 4 results.

Research and earnings timetable

Charles River announced the FDA and Labcorp research agreement on October 22, 2026, covering more than 100 prior studies and 15 FDA-approved products.
Second-quarter 2026 revenue reached USD 1.00 billion, while earnings per share came to USD 3.02 versus USD 2.77 consensus.
Third-quarter 2026 results and the earnings call are scheduled for November 4, 2026.

CRL, US1598641074, Illustration mit AI erstellt.

Charles River Laboratories (ISIN US1598641074) joined the U.S. Food and Drug Administration and Labcorp on October 22, 2026, to develop tools for measuring the abuse potential of new drugs, according to Business Wire. The company is scheduled to publish third-quarter 2026 results on November 4, 2026, according to Charles River Laboratories.

The research has measurable scale

Charles River said it has conducted more than 100 abuse-potential studies and contributed to assessments of 15 FDA-approved products. The new framework will use behavioral-economic models and preclinical data to improve the consistency of regulatory assessments.

What will November 4 clarify?

Second-quarter 2026 revenue was USD 1.00 billion, down 2.7 percent from the prior-year quarter, while adjusted earnings per share reached USD 3.02 against USD 2.77 consensus, according to MarketBeat. The comparison puts the next report in a clear context: earnings execution has held up better than revenue, while the top-line trend remains the central operating question.

Three recent steps in sequence

The company listed one Apollo Orchestrate launch on October 6, 2026, and one Magellan Stem Cells collaboration on October 13, 2026, on its investor-relations page. The FDA and Labcorp agreement followed on October 22, 2026, adding a third research initiative within the same month and bringing the latest announcement to more than 100 studies and 15 FDA-approved products.

The next date is November 4

The next scheduled date is November 4, 2026, for third-quarter results before the market opens and a 9:00 a.m. ET conference call, according to Business Wire. For Charles River Laboratories stock, that report will test whether the second-quarter earnings resilience can coexist with softer revenue.

Market value sets the frame

Charles River Laboratories had a market capitalization of USD 16.6 billion as of October 23, 2026, and its 52-week range was USD 146.20 to USD 351.21. The company is listed on the NYSE under CRL and operates in healthcare and life sciences tools and services.

The further course of trading is shown by the continuously updated real-time quote of Charles River Laboratories stock.